Xarelto (rivaroxaban),a blood thinner used to tread blood clots, is known as a New Oral Anticoagulant (NOAC). This drug was brought to the market largely to replace Coumadin (warfarin). Unlike Coumadin, Xarelto does not require regular monitoring of blood plasma levels, so it is considered to be more convenient. However, it does carry an alleged risk of internal bleeding, and there is no approved reversing agent that can slow such bleeding if it occurs. As a result, litigants have alleged serious injury or even death in a variety of cases. LawyersandSettlements.com quotes the Sunday Business Post in saying that many surgeons in Ireland have stopped using Xarelto because of adverse bleeding.
Motion to Consolidate Xarelto Complaints
In early October 2014, a motion was filed to ask the U.S. Joint Panel of Multidistrict Litigation (JPML) to consolidate various Xarelto lawsuits into a multidistrict litigation (MDL). The motion requested that the JPML consider the Southern Illinois District Court as an appropriate venue for the consolidated litigation. At present, there are a minimum of 21 pending Xarelto lawsuits in 10 U.S. judicial districts. As recently as a few weeks ago, additional suits were filed in New York, Vermont and Florida.
Beginning July 2011, the U.S. Food and Drug Administration approved Xarelto for a widening array of medical conditions. First, Xarelto was approved for use as a preventative measure for those who had hip or knee replacement surgery. Xarelto was prescribed to reduce the chance of deep vein thrombosis and pulmonary embolism. Later in 2011, the FDA approved Xarelto to decrease blood clot risk and stroke risk in those with diagnosed atrial fibrillation. In November 2013, the FDA began to allow its use in treating diagnosed pulmonary embolism and deep vein thrombosis.
Sales of Xarelto Soar
The acceptance of Xarelto by the medical community is illustrated in part by sales figures. Global sales increased from $582 million in 2011 to $658 million in 2012. In 2013, sales skyrocketed to over $2 billion. An estimated 7 million people have now taken Xarelto worldwide, according to the manufacturer.
Have You Been Affected?
If you or a loved one have been adversely affected by internal bleeding allegedly linked to Xarelto or another NOAC, compensation may be available for unpaid medical expenses, pain and suffering, lost wages and long-term care. To discuss the specifics of your personal experience with a drug injury lawyer in Indianapolis that is focused on this area of the law, please contact us. An initial consultation is available without cost or obligation.